The establishment of reference intervals for biomarkers in healthy populations relies on large-scale, standardized cohort data. However, current baseline data for hematology, liver and kidney function, and multi-omics (genomics, transcriptomics, proteomics, and metabolomics) in Chinese healthy populations are constrained by significant regional disparities and insufficient sample sizes, limiting the development of early disease screening markers. To address these challenges, this study aims to: (1) establish a comprehensive database for hematology and liver/kidney function indicators; (2) construct a multi-omics database using blood and sputum samples; and (3) explore the correlations among multi-omics indicators and their associations with demographic characteristics.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Age: 18 - 65 years old, gender not restricted;
2. No clear history of chronic diseases (hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic liver and kidney diseases, tumors, etc.);
3. No infection history in the past 3 months (fever, cough, sore throat, etc.);
4. No use of antibiotics, hormones, immunosuppressants, etc. within the past 1 month;
5. Voluntarily sign the informed consent form and cooperate to complete the follow-up.
Exclusion Criteria:
1. Abnormal laboratory indicators (ALT/AST \> 2 times the upper limit of normal value, Cr \> upper limit of normal value, main indicators of blood routine test are abnormal and have clinical significance);
2. Pregnant or lactating women;
3. Recent (within 3 months) history of surgery, trauma or blood transfusion;
4. Mental illness or cognitive impairment that makes it impossible to cooperate with the research.
Primary outcome measure(s)
Blood routine test — At the time of enrollment
Trial sites (1)
Facility
City
Region
Status
Fifth Affiliated Hospital of Guangzhou Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.